We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Influenza Test Evaluated for Children

By LabMedica International staff writers
Posted on 24 May 2011
A rapid influenza assay has been evaluated for use with elementary school children and compared with a molecular test. More...


The test is a lateral-flow immunoassay that uses monoclonal antibodies specific for influenza viral nucleoprotein antigens and detects and differentiates between influenza A and B.

Public Health specialists at the University of Pittsburgh, (Pittsburgh, PA, USA), collected 278 pairs of nasal swabs from children during home visits during the 2007-2008 influenza season. One swab was tested with the immunoassay, which takes 10 minutes or less, and the other with a real time, reverse transcriptase polymerase chain reaction (RT-PCR). A total of 104 samples were positive by RT-PCR test, and of these, 54/104 (52%) were influenza A and 50/104 (48%) were influenza B.

Only 28/104 (27%), of these influenza-positive samples were detected as positive by QuickVue rapid immunoassay influenza testing. Influenza A accounted for 17 (61%) of the 28 positive tests, and of the remaining 11 (39%) were influenza B. The sensitivity and specificity of rapid influenza testing, using the QuickVue Influenza A+B test (Quidel; San Diego, CA, USA), in the students with influenza like illness who were tested was 27% (28/104) and 97% (168/174), respectively. The overall positive predictive value was 82% (28/34) and 69% (168/244) for negative predictive values. There was no statistically valid correlation between the semiquantitative PCR result and the QuickVue result.

The authors concluded that community testing includes patients who represent the entire spectrum of illness, with the majority exhibiting mild to moderate symptoms and not requiring medical attention. Viral load, technique, and the use of nasal swabs were examined as contributing factors to the low sensitivity of the QuickVue test, but were not found to be explanations for this result. If tests with higher sensitivities in community settings were available, they could be used as a part of an improved surveillance and early warning system for influenza activity and rapid confirmation of outbreaks. The study was published in March 2011, in the journal Influenza and Other Respiratory Viruses.

Related Links:

University of Pittsburgh
Quidel




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.